Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease–Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities by Fischer, Aryeh et al.
182  
Arthritis & Rheumatology
Vol. 71, No. 2, February 2019, pp 182–195
DOI 10.1002/art.40769 
© 2019 American College of Rheumatology and the Association of Physicians of Great Britain & Ireland
S P E C I A L  A R T I C L E
Proceedings of the American College of Rheumatology/
Association of Physicians of Great Britain and Ireland 
Connective Tissue Disease–Associated Interstitial Lung 
Disease Summit: A Multidisciplinary Approach to Address 
Challenges and Opportunities
Aryeh Fischer,1 Mary E. Strek,2 Vincent Cottin,3 Paul F. Dellaripa,4 Elana J. Bernstein,5  Kevin K. Brown,6  
Sonye K. Danoff,7 Oliver Distler,8 Nik Hirani,9 Kirk D. Jones,10 Dinesh Khanna,11 Joyce S. Lee,1 David A. Lynch,6 
Toby M. Maher,12 Ann B. Millar,13 Ganesh Raghu,14 Richard M. Silver,15 Virginia D. Steen,16  
Elizabeth R. Volkmann,17 Ronan H. Mullan,18 David N. O’Dwyer,11 and Seamas C. Donnelly18
INTRODUCTION
Interstitial lung disease (ILD), a group of diffuse parenchy-
mal lung disorders classified together based on specific clin-
ical, radiologic, and histopathologic features, is often associ-
ated with significant morbidity and mortality and is a common 
manifestation in connective tissue disease (CTD) (1). ILD often 
arises within the context of a specific exposure or is associated 
with an underlying CTD. The CTDs are a spectrum of systemic 
autoimmune disorders with significant clinical heterogeneity 
characterized by immune- mediated organ dysfunction, and the 
lung is a frequent target. All CTD patients are at risk of develop-
ing ILD, and those with systemic sclerosis (SSc), polymyositis/
dermatomyositis (PM/DM), and rheumatoid arthritis (RA) are at 
particularly high risk (1,2). ILD may develop at any point in the 
natural history of CTD, is most frequently identified in the set-
ting of an established CTD, and may also be the first clinically 
apparent manifestation of occult CTD. Determining whether a 
patient has a diagnosis of CTD- associated ILD is important, 
as this knowledge may impact treatment decisions, guide sur-
veillance for other concomitant clinical features, and help with 
assessment of prognosis (3).
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The intersection of CTD with ILD is complex and fraught with 
areas of controversy and uncertainty. There are numerous gaps 
in our understanding of why certain CTD populations are more 
likely to develop ILD, but certain phenotypic risk factors have been 
identified. In RA, these include older age, cigarette smoking, male 
sex, rheumatoid factor positivity, anti–citrullinated protein antibody 
(ACPA) positivity, and more severe articular  disease (4–6). In SSc, 
autoantibodies are the most reliable predictor of ILD, with anti–Scl- 
70 being one of the strongest (7). In PM/DM, autoantibody profiles 
also are useful predictors of ILD, especially antisynthetase antibod-
ies (e.g., Jo- 1, PL- 7, PL- 12), anti- PM/Scl antibody, and anti–mela-
noma differentiation–associated protein 5 antibody (8–10). Knowl-
edge of reliable risk factors for ILD development in other CTDs is 
lacking. Since the advent of computed tomography (CT), it has 
been possible to characterize ILD with greater precision than pre-
viously (11,12), yet significant gaps remain with respect to reliable 
determinants of the prevalence of ILD among patients with CTD, 
and there is controversy surrounding whether to implement early 
detection strategies in these patients.
Perhaps the greatest unmet needs for ILD in CTD are in the 
realm of therapeutics. Few effective therapies exist, most deci-
sions about management are based on experience rather than 
evidence, and there remains a desperate need for well- designed 
multicenter clinical trials of both existing and novel agents (13).
With a desire to highlight key areas needing scientific and ther-
apeutic focus in CTD- associated ILD, in 2017 the Association of 
Physicians of Great Britain and Ireland and the American College of 
Rheumatology supported a multidisciplinary panel of international 
clinician- scientists from pulmonology, rheumatology, thoracic radi-
ology, and lung pathology specialties with interests and expertise 
in ILD to convene a 1- day summit on CTD- associated ILD. The 
goals of the summit were to highlight key clinical and research 
aspects of CTD- associated ILD, identify unmet needs, and outline 
future research goals in this complex intersection of diseases. In 
this report we detail the proceedings of this summit, which were 
anchored around 5 domains: 1) clinical, 2) biomarkers, 3) diag-
nostic imaging and histopathology, 4) treatment and clinical trials 
design and outcome measures, and 5) translational research.
Clinical domain
Statement of the problem and current understand-
ing. ILD is among the leading causes of morbidity and mortality 
in patients with CTD (1,2). Our understanding of ILD in the setting 
of CTD is challenged by a combination of factors including the 
systemic nature of the patients’ rheumatologic disease. Patients 
with CTD- associated ILD, compared to those with idiopathic pul-
monary fibrosis (IPF), present with a greater degree of heteroge-
neity and marked variability in natural history. IPF is a devastating 
progressive fibrosing ILD associated with a high burden of mor-
bidity and mortality (14). A clinical diagnosis of IPF is made only 
after careful interpretation of integrated clinical, radiologic, and 
often lung histopathologic data. Classification of IPF is restricted 
to those individuals with a lung injury pattern of usual interstitial 
pneumonia (UIP) based on high- resolution CT (HRCT) scanning 
or surgical lung biopsy, after all known etiologies for UIP—such 
as underlying CTD—have been evaluated and excluded (14). 
Patients with CTD may have a mix of inflammatory and fibrotic ILD 
along with multicompartment lung involvement including airways, 
pleural, and pulmonary vascular disease, which may confound 
determination of the etiology of their respiratory impairment and 
potential responses to therapy. Furthermore, the ability to predict 
progression of ILD in CTD is challenging as some patients develop 
ILD that is mild and nonprogressive, while others have a more pro-
gressive course with unrelenting decline in function as seen in IPF.
Optimal care of patients with CTD- associated ILD requires 
collaboration and close interaction by the rheumatology and 
pulmonology communities. Rheumatologists have begun to 
improve their surveillance for lung involvement in patients with 
CTD, though clear guidelines (and training) have been lack-
ing. Pulmonologists evaluating patients with ILD have become 
more attuned to the demographic, historical, and phenotypic 
features that may suggest an underlying CTD, though their 
level of expertise with that evaluation varies widely. Our under-
standing of natural history has been limited mostly to prospec-
tive observational studies and retrospective analyses, but clini-
cal, pulmonary physiologic, and radiologic data emerging from 
prospective trials may identify those patients at highest risk for 
developing ILD and those who are candidates for treatment 
and participation in clinical trials (15). While there has been 
greater emphasis on a multidisciplinary approach to patient 
care and education of physicians, effective collaboration 
between pulmonologists and rheumatologists still falls short 
due to practical reasons including interest, limited expertise in 
this area, and availability of and access to ancillary resources. 
Collective experience and a recent study demonstrate that 
collaborative efforts can be effective in enhancing patient care 
(16,17).
Challenges and unmet needs. One of the challenges 
in CTD- associated ILD is that the prevalence of ILD among 
different groups of patients with CTD varies so widely (Table 1), 
with the highest estimated prevalence rates noted among 
patients with SSc and those with PM/DM (1,2,18). Severity of 
disease is most notable in patients in whom ILD is predomi-
nantly fibrotic such as patients with UIP as is seen in RA, with 
mortality rates comparable to those of IPF (6,19,20). While 
prevalence may define the frequency of ILD in any given CTD, 
focusing on the severity of disease based on features identified 
by chest imaging, with pathologic correlation when histologic 
data are available, may offer greater insight into prognosis 
compared to a focus on any specific CTD, and may thus guide 
decision- making with regard to treatment and inclusion in clin-
ical trials.
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Efforts to identify CTD patients with ILD or those who are 
at risk of developing ILD require an approach to screening that 
has the dual objectives of identifying early- stage disease and 
more specifically identifying those at greatest risk for progres-
sion and functional decline. Our present approaches do not 
allow us to fulfill either of those screening goals effectively, 
though emerging evidence suggests a framework for screening. 
In RA for example, as highlighted in a recent high- level review 
(6), the pattern of UIP predominates in most series (6,20,21), 
and certain phenotypic features (older age, male sex, history 
of smoking, and ACPA positivity) that may predict a higher risk 
for ILD have been identified in retrospectively studied cohorts. 
However, prospective data are only now being gathered to test 
and validate predictive models that may allow selective and 
targeted screening efforts (22–26). In RA there is a suggestion 
that pulmonary physiologic data can predict decline, though it 
is unclear whether this can serve as the sole screening strategy 
(27). In SSc and PM/DM, retrospective studies have identified 
phenotypic, autoantibody, radiologic, and pulmonary physio-
logic data that identify patients at increased risk for ILD and 
for mortality (28–30). Such understanding has led to the devel-
opment of algorithms utilizing a combination of HRCT and 
pulmonary physiologic data to assess severity of disease and 
offers insights into assessment of prognosis (28–30). Screen-
ing strategies that identify ILD are important in view of evidence 
indicating that immunosuppressive treatment produces mod-
est benefits. Data on utilization of antifibrotic drugs approved 
for use in IPF are not available, but these agents are being 
investigated in ongoing prospective trials.
Proposed future directions. A clearer understanding of 
long- term historical data will require multicenter cooperation using 
prospective databases that encompass phenotypic, pulmonary 
physiologic, radiologic, genomic, and proteomic data that may 
help elucidate factors that can best predict which patients are at 
risk for ILD and for progressive disease. Heightened awareness 
and recognition that lung disease is common among patients 
with CTD should lead to creative and sustained efforts to improve 
education of rheumatologists regarding clinical features of lung 
disease and utilization of pulmonary physiologic data to facilitate 
prompt and appropriate referral, and to forge closer collaborations 
with pulmonology colleagues. For the pulmonologist, dedicated 
education and training is needed to aid in recognizing important 
clinical and historical features that indicate a diagnosis of a CTD 
and to gain better understanding of autoimmune serologies in 
the evaluation in patients with ILD. Much of this can be accom-
plished by greater cooperation between the academic societies of 
the two disciplines, utilizing existing educational opportunities but 
also creating additional learning modalities such as case- based 
online educational modules. Finally, enhanced fellowship training 
in both disciplines with elective rotations in one another’s specialty 
during fellowship, and encouragement of collaborative pulmonary 
and rheumatology fellowship opportunities, will also enhance rec-
ognition of these disorders and will hopefully improve the care of 
patients with CTD- associated ILD.
Biomarker domain
Current understanding and unmet needs. Biomarkers 
refer to a category of objective medical signs that correlate with 
certain aspects of normality or abnormality and may be defined 
as “a characteristic that is objectively measured and evaluated as 
an indicator of normal biologic processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention” (31). 
Given the heterogeneity of ILD complicating CTD, the identifica-
tion of biomarkers is an important endeavor. However, to date 
there are no validated biomarkers for CTD- associated ILD.
Diagnosis of CTD- associated ILD is currently limited to the 
use of clinical data including history, physical examination, pul-
monary function testing, and data from lung imaging and histo-
pathologic studies. In order for biomarkers to become impor-
tant tools for clinical practice, the specific measures should be 
accessible, reproducible, accurate, and clinically useful. Obtain-
ing samples must be feasible, and the risk acceptable. While 
Table 1. Connective tissue disease–associated interstitial lung disease: estimated prevalence rates, lung injury patterns, and clinical presentation* 
CTD Estimated prevalence of ILD† ILD pattern Frequency CTD is occult
Polymyositis, dermatomyositis, 
antisynthetase syndrome
40% NSIP with OP, NSIP, OP, UIP Often
Rheumatoid arthritis 10% clinical, 30% subclinical UIP, NSIP, OP Less often
Sjögren’s syndrome 40% NSIP, UIP, LIP Less often
Systemic sclerosis 30–40% clinical, 80% 
subclinical
NSIP, UIP Less often
Systemic lupus erythematosus 8–12% DAH, NSIP ILD is infrequent
Interstitial pneumonia with 
autoimmune features
100% NSIP, OP, NSIP with OP, UIP, 
LIP
Always
* CTD = connective tissue disease; ILD = interstitial lung disease; NSIP = nonspecific interstitial pneumonia; OP = organizing pneumonia; UIP = 
usual interstitial pneumonia; LIP = lymphocytic interstitial pneumonia; DAH = diffuse alveolar hemorrhage. 
† From refs. 1, 2, 6, 18, 45, 76, and 77. 
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biomarkers in ILD studies may be obtained from lung tissue and 
bronchoalveolar lavage (BAL) fluid, biomarkers obtained from 
peripheral blood would be far better given ease of access, con-
venience, and cost factors. At the same time, analysis of tissue 
or BAL fluid from the site of pathophysiologic activity in the lungs 
is a potentially more promising route for discovering ILD- relevant 
biomarkers than analysis of the blood. This is especially the case 
when other organ involvement in a systemic disease contributes 
to the overall heterogeneity of measured signals in the blood, 
thereby potentially confounding or limiting interpretation of a 
serologic finding (e.g., rheumatoid factor, antinuclear antibody, 
erythrocyte sedimentation rate).
Several challenges need to be met before the acquisition 
of valid biomarkers for CTD- associated ILD can become a real-
ity. A systematic review using an NCBI search strategy with the 
terms “interstitial lung disease,” “connective tissue disease,” 
and “biomarker” was used in preparation for this summit. Case 
reports, case series, studies with inappropriate design or patient 
populations, pediatric studies, and studies with <20 cases were 
excluded from the analysis. The Outcome Measures in Rheuma-
tology (OMERACT) filter was applied to evaluate articles for truth-
fulness, feasibility, and discriminatory ability (32,33). Articles were 
also subjected to analysis of whether the proposed biomarker 
measured an appropriate target domain (34). There were only 23 
articles that passed these initial stages.
Candidate biomarkers have been identified in a number of 
the studies fulfilling the search criteria and passing the  OMERACT 
filter. Chen and colleagues reported a strong association between 
the presence of ILD in RA patients and elevated peripheral 
blood levels of matrix metalloproteinase 7 (MMP- 7) and interfer-
on- γ–inducible protein 10 (CXCL10) as measured by multiplex 
enzyme- linked immunosorbent assay (ELISA). This association 
was confirmed in 2 independent Chinese RA cohorts. The authors 
subsequently validated their findings using a different quantitative 
platform (sandwich ELISA) in a separate cohort of RA patients 
from the US (22). Further work by Doyle and colleagues demon-
strated that a regression model composed of several clinical vari-
ables could be used to identify both clinically evident ILD and sub-
clinical ILD in 2 independent RA cohorts (25). This association was 
significantly improved with the addition of the peripheral blood bio-
markers MMP- 7, surfactant protein D (SP- D), and activation regu-
lated chemokine/CCL18. In the Scleroderma Lung Study (SLS I), 
analysis of serum Krebs von den Lungen 6 and SP- D in peripheral 
blood demonstrated significant associations with parenchymal 
lung disease in SSc patients with ILD (35).
BAL also has proven utility in the assessment of alveolitis 
in SSc. Schmidt et al compared the levels of alveolar cytokines 
in 32 SSc patients, by multiplex ELISA (36). They found higher 
levels of interleukin- 7 (IL- 7), IL- 4, IL- 6, IL- 8, and CCL2 in BAL 
fluid from patients who had ILD. However, their observations 
were limited by the small sample size of the cohort. Though 
potential biomarkers for CTD- associated ILD from different 
sources including peripheral blood and BAL have been studied 
in patient cohorts, to date the use of these biomarkers has not 
been adopted in everyday practice. Further prospective studies 
are clearly needed.
Overall, the current evidence in support of specific candidate 
biomarkers consists predominantly of results obtained from rel-
atively small retrospective or cross- sectional studies with limited 
power. Most published studies have been conducted at single- 
center academic institutions and results may not be broadly 
applicable. Furthermore, given the clinical heterogeneity of CTD- 
associated ILD, it is likely that no single biomarker will have utility 
in diagnosis and prognosis, or act as a measure of disease pro-
gression and response to therapy.
Proposed future directions. A number of future direc-
tions are proposed to address these unmet needs and chal-
lenges in CTD- associated ILD biomarker development (Fig-
ure  1). Ideally, biomarkers will be used to achieve a number 
of specific aims in CTD- associated ILD. They may facilitate 
screening or diagnosis to identify individuals at high risk of 
developing ILD, or alternatively to identify those with early, pre-
clinical disease. In addition, biomarkers may be used to risk- 
stratify patients at baseline and assess prognosis. They may 
provide data on disease progression and/or response to ther-
apy. Furthermore, they may serve as surrogate markers for use 
as clinical trial end points or as tools to provide mechanistic 
pathophysiologic insight. Biomarker studies in other forms of 
ILD, namely IPF, have led to significant ongoing improvements 
in our understanding of the pathophysiology of pulmonary 
fibrosis (37–39), and these data exemplify the types of stud-
ies that may be considered in future investigations addressing 
CTD- associated ILD.
In conclusion, the development of accurate and practical 
biomarkers for diagnosis, prognosis assessment, analysis of dis-
ease progression, and evaluation of treatment response in CTD- 
associated ILD is an important research endeavor with consid-
erable implications related to clinical trials and clinical practice. 
Further deliberations by multidisciplinary stakeholders are needed 
to determine the best course for the future development of CTD- 
associated ILD biomarkers.
Diagnostic imaging/histopathology domain
Imaging. Current understanding. CT imaging of the 
chest plays a critical role in identifying and characterizing CTD- 
associated ILD and in longitudinal follow- up when ILD is present. 
Its use must also be balanced against longer- term risk associat-
ed with radiation exposure. In addition to ILD, clinically important 
findings that may be identified on CT include features that indi-
cate airways, pulmonary vascular, or pleural disease. Any pattern 
of ILD may occur in any of the CTDs, and the estimated preva-
lence of specific patterns varies by disease (40–42) (Table 1). CT 
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can reveal asymptomatic lung disease in a substantial proportion 
of patients with CTD, and these changes may  progress slowly 
over time (Figure 2).
Unmet needs. The utility of CT in screening for early CTD–
associated ILD is unknown. If ILD is present, we do not know 
how to identify patients in whom it is likely to progress, and 
optimal follow- up and treatment of patients with early changes 
remains unclear. Quantitative methods are increasingly being 
used for determining the extent of disease evidenced on CT, 
and have been used to document decreases in the extent of 
CTD- associated ILD in clinical trials (43,44). However, a stand-
ardized quantitative approach has not yet been developed, 
and the sensitivity of these techniques in identifying short- term 
longitudinal change is unknown.
Figure  1. Proposed future investigative directions for the development of connective tissue disease–associated interstitial lung disease 
biomarkers. DLco = diffusing capacity for carbon monoxide; FVC = forced vital capacity; HRCT = high- resolution computed tomography; BALF = 
bronchoalveolar lavage fluid.
Figure 2. Progression of interstitial lung abnormalities in a patient with systemic sclerosis, as demonstrated by computed tomography. The 
image on the right was obtained 3 years after the image on the left.
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Proposed future directions. There is a critical need for as-
sembly of prospective cohorts of well- characterized patients 
with SSc, RA, and PM/DM/antisynthetase syndrome who would 
undergo CT at enrollment, with follow- up scanning at specific 
intervals. This could be achieved through a multi- institutional 
network, and perhaps by collaboration with industry to share 
CT scans performed in the context of clinical trials. Specifical-
ly, achievement of the following could yield valuable insights: 1) 
elucidation of the relationship between CT- determined pheno-
type (UIP, nonspecific interstitial pneumonia [NSIP], organizing 
pneumonia, lymphocytic interstitial pneumonia) and progression 
of CTD- associated ILD or response to treatment, 2) elucidation 
of the relationship between baseline extent of abnormality on 
quantitative CT and both short- term and medium- term outcome 
(death, progression, improvement), and 3) development and 
validation of techniques for phenotyping and quantifying CTD- 
associated ILD.
Histopathology. Current understanding. The decision on 
whether histologic examination of the lung would be useful in 
cases of CTD requires an analysis of potential benefit versus risk 
of an invasive procedure. Microscopic examination of surgical 
lung biopsy specimens from patients with CTDs often shows 
histologic clues indicating that the etiology is of an autoimmune 
nature (Table 2) as opposed to the findings being idiopathic or 
the result of other disease (45–47). Some of these histologic 
features (e.g., fibrosis) have been shown to be related to prog-
nosis, but none have been influential in determining treatment 
decisions (48–50). These cases often do not fit into a single his-
tologic category when using the criteria for idiopathic interstitial 
pneumonia (IIP), and instead show overlapping features of 2 or 
more entities (51). The risk of mortality from surgical lung biopsy 
was recently evaluated. In 2 large series in the US and the UK 
(52,53), the 30- day mortality rate with elective surgical lung bi-
opsies was 1.5% and 1.0%, respectively. However, in the US se-
ries, the risk of death was 6.0% in patients with CTDs. The odds 
ratio for 90- day mortality in patients with CTD was similar to that 
in the overall cohort in the UK study. The risk of mortality was in-
creased in patients who were being treated with glucocorticoids.
Whether to obtain a surgical lung biopsy depends on the clin-
ical situation, and several frequently encountered scenarios were 
considered, and consensus reached, by the summit participants: 
1) A patient has known CTD, has been shown clinically and/or 
radiologically to have ILD, and the ILD is progressing typically (Fig-
ure 3). In this case, the participants recommended not obtaining a 
biopsy because the results would not alter the treatment strategy. 
2) A patient has certain clinical or serologic features suggesting 
possible CTD- associated ILD but does not meet established cri-
teria for a CTD. In this case, the consensus was that a biopsy 
may be performed to assess whether specific histologic features 
support the presence of an autoimmune ILD (e.g., “interstitial 
pneumonia with autoimmune features”) that might impact treat-
ment strategies. 3) A patient has a known CTD but has an atyp-
ical clinical picture suggesting hypersensitivity pneumonitis, has 
drug- induced lung toxicity, or has an atypical radiologic pattern. 
In this case, the participants agreed that biopsy may be indicated 
Table 2. Histologic features associated with underlying connective 
tissue disease 
Prominent lymphoid aggregates with germinal center 
formation
Increased lymphocytic inflammation with plasma cell 
infiltrates
Overlapping features of peripheral honeycombing with 
central fibrosis
Involvement of multiple pulmonary compartments  (interstitial 
disease with additional small airway, vascular, or pleural 
disease)
Nonspecific interstitial pneumonia pattern with additional 
organizing pneumonia
Figure 3. Surgical lung biopsy specimen from a patient with known 
connective tissue disease–associated interstitial lung disease (ILD) in 
whom the ILD was progressing typically, showing a mixed pattern 
of subpleural and centrilobular fibrosis with prominent lymphoid 
aggregates. Bar = 1 mm.
Figure  4. Surgical lung biopsy specimen from a patient with 
rheumatoid arthritis treated with biologic agents who developed 
nodular ground- glass opacities seen on computed tomography. The 
biopsy demonstrates granulomatous Pneumocystis pneumonia. 
Bar = 400 μm.
FISCHER ET AL 188    |
in order to differentiate between hypersensitivity pneumonitis, 
drug toxicity, or an infectious etiology (Figure 4) rather than CTD- 
associated ILD.
The availability of antifibrotic therapies raises the question of 
whether a biopsy may reveal certain histologic features that would 
guide therapy (e.g., whether a CTD patient with a UIP pattern of 
fibrosis should be offered antifibrotic therapy). However, there are 
currently no available data to answer this question.
Proposed future directions. The recent advances with the 
technique of cryobiopsy (54)—and wider application of this in-
novative procedure—may provide valuable insights into lung 
histopathology in CTD- associated ILD. However, as recently 
emphasized by an international cryobiopsy working group (55), 
the technique has not yet been standardized, and its place in 
the diagnostic algorithm of ILD remains to be defined. In part, 
this reflects concerns over the diagnostic yield and safety of the 
procedure, along with the rapid spread of the technique with-
out safety or competency standards (55). Another limitation and 
concern regarding cryobiopsy is the substantial procedural var-
iability among centers and interventional pulmonologists (55). 
Usual practice is not to perform a surgical lung biopsy in “typi-
cal” scenarios as discussed above, but the advent of cryobiop-
sy may change this paradigm by providing a safer and easier 
approach to obtaining parenchymal lung tissue. It remains to be 
seen whether cryobiopsy will become a common procedure in 
the evaluation of ILD, but if it does, we would anticipate that 
access to far greater numbers of histopathologic samples in 
CTD- associated ILD will allow for a greater understanding of the 
correlations between lung injury patterns on HRCT and histo-
pathology. Cryobiopsy might also lead to insights into whether 
specific autoimmune histopathology features are more predictive 
of underlying CTD and could help with refining of the histopatho-
logic criteria for interstitial pneumonia with autoimmune features 
(45). We anticipate a need for approaches based on imaging or 
histopathology to optimize treatment strategies, i.e., antiinflam-
matory versus antifibrotic therapies—and having more access to 
lung tissue should enhance such approaches as histopathologic 
findings remain the gold standard to define presence of fibrosis.
Treatment/clinical trials domain
Statement of the problem and current understand-
ing. The clinical management of CTD- associated ILD is challeng-
ing, as 1) the natural history remains poorly understood though 
with significant recognized disease and individual patient het-
erogeneity, 2) there are no approved therapies, and 3) with the 
exception of recent clinical trials in SSc- associated ILD (44,56,57), 
there has been a paucity of interventional clinical trials. A simi-
lar dilemma existed in IPF, but over the last decade the perfor-
mance of multiple large multicenter clinical trials in IPF led to a 
much better understanding of the disease trajectory, and to the 
availability of approved antifibrotic therapy. There are significant 
challenges to embarking on large clinical trials in CTD- associated 
ILD, but the substantial unmet need, especially in RA- associated 
and SSc- associated ILD, is a powerful incentive for overcoming 
these obstacles.
Phenotypic heterogeneity and natural history diver-
sity. In clinical trials the goal is to recruit subjects with diseases 
of uniform pathobiology and natural history (i.e., homogeneity). 
 However, the CTD- associated ILDs have complex systemic man-
ifestations, multicompartment pulmonary disease, and a highly 
variable natural history. Their interstitial component can be clas-
sified according to the recognized pathologic patterns of the IIPs 
(58). The most common histologic patterns associated with CTD 
are NSIP and UIP, but any of the pathologic patterns can occur. 
Given that the systemic disease in CTD is immune driven, there is a 
rationale to believe that humoral and T cell–directed inflammatory 
processes contribute to the lung injury. However, many patients 
with CTD- associated ILD develop progressive ILD despite treat-
ment with a variety of immunomodulatory agents that control the 
underlying disease.
Some CTD patients have clear symptoms of lung disease 
at the time of ILD diagnosis. Others have “subclinical” disease, 
i.e., radiologic findings suggestive of ILD in the absence of symp-
toms, and some have no evidence of lung disease at the time of 
the CTD diagnosis, but are at risk of developing ILD. There are 
no consensus guidelines that define either subclinical or clinically 
overt ILD in this context. Any potential definition would have to 
include subjective reports (symptom scores), chest imaging with 
qualitative and quantitative HRCT scoring, and pulmonary physi-
ology assessment. For instance, subclinical CTD- associated ILD 
could be defined according to a threshold in extent and pattern 
of abnormality on HRCT in the setting of normal pulmonary phys-
iology and the absence of respiratory symptoms. Clinically overt 
CTD- associated ILD could be defined as HRCT- detected abnor-
mality plus lung function impairment or decline and/or respiratory 
symptoms. This potentially offers a unique opportunity to initiate 
clinical trials for all “stages” of disease and therein generate much- 
needed natural history data.
Proposed future directions. One option to improve study 
subject homogeneity is to pool subjects based on the underlying 
pathologic pattern of the ILD rather than the specific CTD (e.g., 
grouping patients with a UIP pattern of disease regardless of the 
underlying CTD). A limitation to this approach is that biopsy is 
infrequently performed in CTD- associated ILD, so the pathologic 
pattern cannot always be confirmed. Even when a biopsy is per-
formed, a “classic” UIP histologic pattern is relatively uncommon, 
and “mixed” patterns are frequent. The radiologic pattern seen on 
HRCT of the chest is often used as a surrogate for lung biopsy, 
and thereby to classify the type of CTD- associated ILD. This is 
common practice in the IIPs based on consensus criteria, and it 
seems intuitively attractive to extrapolate this HRCT classification 
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to CTD- associated ILD. However, HRCT patterns have not been 
as robustly correlated with pathology in CTD- associated ILD. The 
relationship between HRCT patterns and disease progression is 
reasonably well established in idiopathic disease (e.g., a UIP pat-
tern is associated with a worse outcome than a non- UIP pattern), 
but comparative studies in CTD- associated ILD are scarce. There 
is a pressing need for longitudinal HRCT- based studies in CTD- 
associated ILD. Presently, it may be more practical to perform 
trials according to the underlying CTD and subsequently stratify 
according to HRCT pattern.
With regard to natural history diversity, an attractive investi-
gational model would be to enroll unselected patients with CTD 
into a multicenter longitudinal observational cohort, in which 
both incident and prevalent cases at all stages could be stud-
ied  (Figure 5). In isolation, unbiased observational cohort studies, 
though informative, can be difficult to perform and fund. A thera-
peutic intervention study is more likely to be attractive and is easy 
to justify in clinically overt CTD- associated ILD, but in patients 
who have subclinical ILD or are at risk for ILD the justification is 
more nuanced. A number of these at- risk patients will develop 
ILD, but the proportion and time scale are uncertain. Moreover, 
some of these patients are likely to already be receiving treatment 
for extrapulmonary features of their CTD. Such a trial design was, 
however, recently applied in a phase III study of anti–IL- 6 antago-
nist treatment of patients with early SSc and elevated acute- phase 
reactant levels (59). Treatment, in the context of a trial, could only 
be justified if the intervention is known to have low risk of harm. 
Mycophenolate mofetil (MMF) is a commonly used immunosup-
pressant in various CTD- associated ILDs. In early diffuse SSc, it 
is used for management of skin fibrosis, although there are dif-
ferences among practices. Consideration can be given to case–
control or longitudinal observational cohorts to assess the incident 
cases of ILD in patients who have been treated with MMF versus 
those who have not, accounting for covariates such as duration of 
disease, ethnicity, autoantibody status, and geographic distribu-
tion. The safety profile is good, and a randomized controlled trial 
of MMF for primary prevention of ILD in at- risk patents with CTD 
may be ethically justifiable.
Addressing systemic manifestations. Well- executed 
clinical trials demand a defined standard of care. For subjects 
at risk for developing CTD- associated ILD and those with sub-
clinical ILD, this would be “no- treatment” for the underlying ILD. 
While there are currently no approved drugs for CTD- associated 
ILD, there are ongoing late- phase trials with pirfenidone and 
nintedanib, drugs currently approved for IPF, that include patients 
with clinically significant CTD- associated ILD. Many clinicians pre-
scribe glucocorticoids and/or other immunomodulatory drugs, 
commonly cyclophosphamide (CYC), MMF, or azathioprine, for 
CTD- associated ILD. In rapidly progressing CTD- associated ILD, 
which can occur in DM, for example, these and other agents are 
accepted as appropriate therapy. A similar case may be made for 
SSc- associated ILD, in which there is some prospective trial evi-
dence of efficacy of CYC and MMF (44,57), especially in specific 
subgroups. Thus, while placebo- controlled studies may still be 
ethically viable for patients with CTD- associated ILD, the fact that 
routine care often includes immunomodulatory therapies makes 
such trial design more difficult to successfully recruit patients for 
and implement. Trial stratification methodology could be utilized to 
ensure the veracity of results.
End points for clinical trials in CTD- associated 
ILD. Trial end points are often dependent on the phase of 
study and study aims. For subjects recruited into a trial for 
CTD patients at risk for ILD, the end point would be the 
development of subclinical or clinically overt ILD, as defined 
a priori. There have been few efficacy trials in the setting of 
clinically overt CTD- associated ILD, and primary end points 
are not well established. In IPF, mortality, while clinically rel-
evant, does not appear to be a feasible primary end point 
(60). Because the association between decline in forced vital 
capacity (FVC) and subsequent death is high, change in FVC 
is now the established primary end point in IPF efficacy trials 
and has been recognized by regulatory agencies as a surro-
gate for mortality. In contrast to IPF, our understanding of the 
behavior of CTD- associated ILD within a trial setting, in terms 
of change in lung function, hospitalization, and mortality, is 
very limited. It is unlikely that studies in CTD- associated ILD 
powered on a mortality end point could be practically per-
formed. There are data to confirm that change in FVC corre-
lates with mortality in CTD- associated ILD as it does in IPF 
(27,61), but hospitalization rates are unknown. Tools, such as 
blood biomarkers and/or risk scores to improve the ability to 
determine “predicted events” during the period of observa-
tion, would be invaluable.
Figure  5. Suggested disease population stratification, and 
corresponding primary trial outcome, for interstitial lung disease (ILD) 
clinical trials in patients with connective tissue disease.
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In the absence of an established relevant single end point, a 
composite “event- driven” end point may be a tempting solution, 
comprising, for example, ≥10% decline in FVC, ≥15% decline in 
diffusing capacity for carbon monoxide, hospitalization, and/or 
death (62,63). However, the use of composite end points pres-
ents its own difficulties that may limit interpretation of the data 
(64). Finally, patient- reported outcomes (PROs), including dys-
pnea, cough, or quality of life, should be considered in all  efficacy 
trials. The OMERACT group recently provided consensus- based 
domains and PROs for use in clinical trials. Although some 
 PRO- related instruments, such as the Mahler dyspnea index and 
St. George’s Respiratory Questionnaire, have been validated via 
clinical trials (SLS- I and II) (65) and observational cohort studies, 
many have not. Therefore, ongoing and future trials should proac-
tively validate outcome measures. Table 3 summarizes ongoing 
 clinical studies in CTD- associated ILD that have been submitted 
to  ClinicalTrials.gov.
In conclusion, the unmet need for therapy in CTD- 
associated ILD, combined with a plethora of potential antifi-
brotic drugs in industry pipelines, demands a new age of clin-
ical trials. Lessons learned from studies in IPF suggest that 
recruitment of patients into well- designed studies can both 
increase understanding of the natural history of disease and 
lead to the discovery of effective treatments. Recruitment of 
CTD patients from the full spectrum of disease, i.e., from those 
at risk for ILD to those with clinically overt CTD- associated 
ILD, is ambitious and would require multicenter cooperation, 
but offers the potential for dramatically increasing our knowl-
edge in these understudied disorders.
Translational research domain
The purview of translational research in CTD- associated 
ILD is exceptionally broad. In this section we focus on several 
themes identified by summit participants as being of particu-
lar relevance due to high levels of future promise, as well as 
addressable barriers to progress. The discussion will be divided 
into 1) databases and bioregistries, 2) technology for precision 
medicine, 3) quality of life outcome measures, and 4) animal 
models.
Databases and bioregistries. Statement of the problem. 
While randomized controlled trials remain the gold standard 
for hypothesis- driven clinical research questions on treatment 
efficacy, the information contained in clinical registries and bio-
repositories offers unique opportunities for advancing our un-
derstanding of CTD- associated ILD. Particularly in the context 
of rare diseases such as CTD- associated ILD, maximizing the 
use of existing registries and biorepositories will be necessary to 
form the groundwork for targeted clinical trials.
Current understanding. The accumulation of real- world reg-
istry data over time provides a more dynamic and evolving picture 
of disease course, which is more generalizable and relevant to the 
real- world patient population (66). Targeted biologic sample re-
positories, particularly when aligned to clinical registry information, 
may be used with maximal effect both to specifically inquire into 
the connected contributions of genetic susceptibility, environmen-
tal, and lifestyle factors in influencing disease pathogenesis and 
to develop a future individualized precision medicine approach.
Challenges and unmet needs. There are significant bar-
riers to data sharing when clinical and biologic registries are 
designed within disconnected, institutional “silos of informa-
tion” or when there is no available technological platform for 
data sharing between institutions at a national or international 
level. Differences in defining the terms of reference of diseases 
for inclusion into disease registries, or in the precise domains 
of clinical information stored, prevent clinical equivalence be-
tween registry data sets, which in turn prevents the merging of 
information between research groups. For biologic samples, 
variations in sample collection and processing can lead to 
variations in the quality of available biobanked material and 
may affect their suitability for sample collaboration between 
groups. This is of particular importance with rare diseases, for 
which larger populations are needed to enable sufficient col-
lection of relevant material.
Proposed future directions. A more collaborative ap-
proach from the research community is needed to maximize 
scientific output, with an emphasis on improved sharing of 
available data and on the standardization of future data col-
lection through the formation of national and/or international 
disease registries. One such effort has been recently launched 
by the Pulmonary Fibrosis Foundation (PFF) with the creation 
of a large network of PFF Care Centers around the US. Within 
the PFF Care Network a collaborative PFF Registry was estab-
lished, which now includes >2,000 patients with diverse forms 
of ILD. High- quality clinical data are being collected, there is 
an accompanying biorepository, and a potentially valuable re-
search database will be available for access by independent 
investigators (https://www.pulmonaryfibrosis.org/medical- 
community/pff-patient-registry).
Technology for precision medicine. Statement of the 
problem and current understanding. In the pursuit of truly per-
sonalized medicine, the capacity to monitor individuals in their 
unique environments should be paramount. While a number of 
technologies have emerged to assess physiology (e.g., heart 
rate, blood pressure), mobility (accelerometry), and even to 
measure PROs on a daily basis, this technology has not ade-
quately evolved to include outcomes relevant in CTD- associated 
ILD, nor has it been adopted in CTD- associated ILD research. 
The thoughtful proactive development and implementation of 
technology will provide a powerful new tool for research, includ-
ing the assessment of therapy and potentially direct therapeutic 
interventions for CTD- associated ILD.
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Challenges and unmet needs. There are technological barri-
ers to progress. The pace of technological advancement in infor-
mation systems, including mobile technologies, has outstripped 
the rate of progress seen in health care information sharing. The 
academic health care community runs the risk of losing oppor-
tunities to improve and shape the quality and quantity of data 
Table 3. Pending or currently recruiting clinical trials in CTD- associated ILD (as of September 2018)* 
Trial name
ClinicalTrials.
gov identifier Study type Disease entity
Participants  
(target or  
estimated) End point
Abatacept in RA- ILD 
(APRIL)
NCT03084419 Interventional 
(phase II open 
label)
RA- ILD 30 No. of participants 
without significant 
decrease (≥10%) in 
FVC following 
abatacept treatment
Phase II Study of 
Pirfenidone in 
Patients With RA- ILD
NCT02808871 Interventional 
(phase II)
RA- ILD 270 Incidence of the 
composite end point 
of decline in FVC  
(% of predicted) of 
≥10% or death
BI 1199.247: Efficacy and 
Safety of Nintedanib 










600 Annual rate of decline 
in FVC (in ml) over  
52 weeks
BI 1199.214: A Trial to 
Compare Nintedanib 






SSc- ILD 520 Annual rate of decline 
in FVC (in ml)






SSc- ILD 150 Change from baseline, 
measured at 
3- month intervals, in 
the mean FVC
Study to Compare the 
Efficacy of 
Mycophenolate 
Mofetil in Systemic 





SSc- ILD 60 Change from baseline 
in FVC at 6 months, 
after treatment with 
oral mycophenolate 
mofetil or placebo
Abituzumab in SSc- ILD NCT02745145 Interventional 
(phase II)
SSc- ILD 22 Annual rate of absolute 








20 Primary outcome 
criterion for efficacy 
will be the % change 
in FVC from baseline 
visit to week 24 
between the 2 
treatment arms 
(standard of care/






NCT01862926 Interventional CTD- ILD 116 Absolute change in FVC 
(time frame 48 
weeks)
* CTD- associated ILD = connective tissue disease–associated interstitial lung disease; RA- ILD = rheumatoid arthritis–associated ILD; FVC = 
forced vital capacity; SSc- ILD = systemic sclerosis–associated ILD. 
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 platforms that may be used to further enrich the information avail-
able for research.
Proposed future directions. Significant opportunities exist 
for the research community to influence the development of re-
search technology, including mobile technologies, to enhance 
the type and quality of data collection. This could be achieved 
through partnership with biotechnology and engineering research 
communities, and through engagement with patient- centered 
organizations to ensure that both the research community and 
the patients themselves benefit from future partnerships.
Quality of life outcome measures. Statement of the 
problem and current understanding. Little is understood about 
the impact of CTD- associated ILD on daily living, including 
quality of life (QoL). Challenges to studying and understanding 
the effects of CTD- associated ILD on health- related QoL in-
clude the differing organ manifestations and effects of specific 
CTDs and elucidation of the pulmonary and extrapulmonary 
contributions to QoL. Nonetheless, it is critical to understand 
how patients experience disease as we assess the impact of 
treatments and other interventions. PRO questionnaires are 
designed to assess the influence of disease on patient func-
tion and individual subjective life experience. They remain an 
important outcome measure, due to both their reproducibility 
in quantifying the impact of disease severity and their sensitivity 
to change.
Challenges and unmet needs. The evaluation of how a 
specific disease impacts QoL for patients with simultaneously 
overlapping symptoms of ILD and systemic disease manifes-
tations presents clear challenges. While some rheumatic dis-
ease–specific QoL instruments, including the Systemic Sclero-
sis QOL questionnaire (67), contain domains that are specific 
for respiratory manifestations of disease, others, including the 
Rheumatoid Arthritis Quality of Life questionnaire (68), which 
was validated using RA patients without ILD, have not been 
designed to determine the specific impact of RA- associated 
ILD on health- related QoL. Although efforts have been made 
to validate lung- specific QoL measures such as the King’s brief 
ILD questionnaire for ILD other than IPF, other measures, in-
cluding the St. George’s Respiratory Questionnaire, which was 
initially designed for patients with chronic obstructive pulmo-
nary disease, have been subsequently validated for patients 
with IPF but not those with CTD- associated ILD (69,70).
Proposed future directions. Future work is needed to de-
termine whether a new QoL tool should be designed, tested, 
and validated in collaboration with CTD- associated ILD patients 
to fully reflect all disease- specific impacts on QoL. Alternative-
ly, consideration should be given to whether an existing ge-
neric, and/or symptom- specific tool that has previously been 
validated in IPF or a CTD can be tested and validated in the 
CTD- associated ILD population. The establishment of a QoL 
outcome measure working group is needed in order to obtain 
consensus on whether such instruments should be symptom 
specific, disease specific, or generic (such as the Short Form 
36 QoL questionnaire) (71). Validation testing of candidate QoL 
outcome measures, with engagement of patient- centered or-
ganizations, should be performed to assess their accuracy in 
determining association with disease severity and sensitivity to 
change.
Table 4. Summary of proposed future directions in connective tissue 
disease–associated interstitial lung disease (CTD- associated ILD)
Standardized international criteria for the classification of 
CTD- ILD
Deliver international guidelines that standardize clinical, 
radiologic, histopathologic, and biologic parameters for 
the diagnosis and classification of CTD- ILD
Defining the natural history of CTD- ILD
Deliver multicenter global clinical networks of well- defined 
disease groups, encompassing longitudinal integrated 
collections of phenotypic, physiologic, radiologic, ge-
nomic, and biologic data 
Clinical care
Deliver multidisciplinary clinics for rheumatology, pulmon-
ology, and allied health care professionals to enhance 
patient care
Cross- disciplinary clinical training 
Deliver cross- disciplinary fellowship clinical training oppor-
tunities for medical graduates
Biomarker development 
Deliver precision medicine–based biomarker platforms to 
guide the optimal therapies to the individual patient
Early screening strategies for ILD
Develop and utilize early detection strategies that identify 
ILD earlier and ultimately predict those at highest risk for 
disease progression
Integration of imaging and histopathology
Generate ILD imaging repositories across the spectrum of 
CTD- associated ILD that correlate with histopathologic 
specimens
Refine cryobiopsy techniques to enrich the availability of 
parenchymal lung tissue specimens
Clinical trials of future interventions in CTD- ILD
Validate CTD- specific trial end points
Incorporate novel technologies to validate quality of life end 
points and patient- reported outcome measures
Develop and incorporate composite end points specific to 
CTD- ILD
Develop an integrated clinical, radiologic, laboratory, and 
biologic database solution that aligns large data sets and 
allows maximum interrogation
Translational research
Form shared national/international registries with biologic 
repositories
Create new, and optimize existing, quality of life measures 
in CTD- ILD
Develop animal models of CTD- ILD
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Animal models. Statement of the problem, current un-
derstanding, and unmet needs. Animal models provide a crit-
ical tool in identifying relevant biologic pathways in disease as 
well as providing a model to test therapeutic agents. To better 
understand the pathogenesis of fibrotic lung diseases, a num-
ber of animal models have been developed. Recent advances 
have allowed for the development of models to study targeted 
injuries of type II alveolar epithelial cells, fibroblastic autono-
mous effects, and targeted genetic defects (72). However, 
there are few models of CTD- associated ILD. Although a mod-
el of RA- associated ILD in SKG mice has been described (73), 
other animal models for CTD, including in tight- skinned mice, 
either have not been characterized for lung disease or do not 
manifest lung disease (74). It remains uncertain whether mu-
rine models of fibrotic lung disease, which include bleomycin- 
induced, radiation- induced, or adoptive cell transfer models 
of lung fibrosis (72), are sufficiently similar to human CTD- 
associated ILD to be of use in identifying molecular targets for 
drug development (75).
Proposed future directions. An inventory of currently ex-
isting animal models of ILD, documenting their disease equiv-
alence to specific manifestations of human CTD- associated 
ILD as well as any known overlap of the recognized molecular 
mechanisms of human and murine disease, is needed. Where 
adequate animal models do not currently exist, funding and re-
search efforts will be needed to develop better animal models of 
CTD- associated ILD that more closely reflect the human condi-
tion and are therefore relevant for disease pathway evaluation 
and drug development in preclinical studies.
Summary
This document summarizes the proceedings of a 
recent summit on CTD- associated ILD attended by a multi-
disciplinary panel of international clinician- scientists with 
expertise in CTD- associated ILD. Key clinical aspects are 
outlined, and a variety of research initiatives are proposed 
(Table  4) with the aim of addressing the many unmet needs 
and challenges within the complex intersection between CTD 
and ILD. Our hope is that further multidisciplinary collabora-
tion around the research into and care of patients with CTD- 
associated ILD will lead to greater disease awareness, earlier 
disease detection and diagnosis, implementation of interdisci-
plinary treatment approaches with novel therapeutic agents, 
and, ultimately, improved quality of life and outcomes for those 
who are affected by these diseases.
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